Get the Stockscreener App
1.75
7.36%
0.12
Citius Oncology Inc stock is traded at $1.75, with a volume of 281.57K.
It is up +7.36% in the last 24 hours and up +6.06% over the past month.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
See More
Previous Close:
$1.63
Open:
$1.63
24h Volume:
281.57K
Relative Volume:
0.19
Market Cap:
$137.15M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+3.55%
1M Performance:
+6.06%
6M Performance:
+49.57%
1Y Performance:
-4.89%
1-Day Range:
$1.63
$1.80
1-Week Range:
$1.57
$1.82
52-Week Range:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.75 | 137.15M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
Citius Oncology Conducts Public Offering of Stock - MSN
Citius Oncology Announces Closing of $9.0 Million Public Offering - ADVFN Brasil
Citius Oncology files prospectus supplement to update S-1 registration By Investing.com - Investing.com Australia
Citius Oncology files prospectus supplement to update S-1 registration - Investing.com
RSI Suggests Rebound May Be Near in Citius Oncology Inc.M&A Rumor & AI Driven Stock Movement Reports - classian.co.kr
Trading Bots Trigger Alerts on Citius Oncology Inc. ActivityGold Moves & Daily Momentum Trading Reports - classian.co.kr
Citius Oncology Inc. Added to High Probability Setup ListWall Street Watch & Free Real-Time Volume Trigger Notifications - newsimpact.co.kr
Will Citius Oncology Inc. Benefit From Broader Market BounceJuly 2025 Review & Entry and Exit Point Strategies - classian.co.kr
Published on: 2025-08-17 14:00:03 - mustnews.co.kr
Is Citius Oncology Inc. exposed to currency risks2025 Volume Leaders & Reliable Momentum Entry Alerts - sundaytimes.kr
Is Citius Oncology Inc. showing insider buyingWeekly Investment Summary & Fast Entry Momentum Trade Alerts - thegnnews.com
Citius Pharmaceuticals shares fall 3.85% intraday after reporting fiscal third quarter results and raising $12.5 million in financings. - AInvest
Citius Oncology Inc. stock chart pattern explained2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - Newser
Identifying reversal signals in Citius Oncology Inc.Earnings Trend Report & Real-Time Market Sentiment Alerts - Newser
Citius Oncology Beats Fiscal Q3 EPS - AOL.com
Citius Oncology Beats Q3 EPS Estimates with $0 Revenue - AInvest
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last year - TipRanks
LYMPHIR Launch Readiness vs. Cash Shortfall: Citius Oncology Raises $9M - Stock Titan
Risk adjusted return profile for Citius Oncology Inc. analyzedPrice Forecast Based on AI Analysis - Newser
Citius Oncology Announces Pricing of $9.0 Million Public Offering - ADVFN Brasil
Smart tools for monitoring Citius Oncology Inc.’s price actionHigh Yield Signals with Entry Timing - Newser
Citius Oncology Inc. stock trend outlook and recovery pathStrategy Chart for Real-Time Trade Flow - Newser
Chart overlay techniques for tracking Citius Oncology Inc.Free Capital Protection Trading Strategies - Newser
Is Now a Good Time to Reenter Citius Oncology Inc.Watchlist for Low Risk High Return Stocks Updated - beatles.ru
Citius Oncology IncAnticipates Commercial Launch of Lymphir in 2025 - 富途牛牛
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators - Benzinga
What analysts say about Citius Oncology Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What institutional investors are buying Citius Oncology Inc. stockInvest smarter with expert stock recommendations - Jammu Links News
What is the risk reward ratio of investing in Citius Oncology Inc. stockUnlock exclusive trading strategies for gains - Jammu Links News
How volatile is Citius Oncology Inc. stock compared to the marketGet professional advice for portfolio optimization - Jammu Links News
Does Citius Oncology Inc. stock perform well during market downturnsUnlock real-time stock alerts for quick profits - Jammu Links News
How strong is Citius Oncology Inc. company’s balance sheetSkyrocketing returns - Jammu Links News
What are the latest earnings results for Citius Oncology Inc.Free Stock Market Trend Analysis - Jammu Links News
Why is Citius Oncology Inc. stock attracting strong analyst attentionAchieve breakthrough investment performance - Jammu Links News
What is Citius Oncology Inc. company’s growth strategyBuild a portfolio for long-term financial success - Jammu Links News
Should I hold or sell Citius Oncology Inc. stock in 2025Capitalize on market trends early - Jammu Links News
What drives Citius Oncology Inc. stock priceGet timely market insights for better trades - Jammu Links News
What are analysts’ price targets for Citius Oncology Inc. in the next 12 monthsFree Daily Trading Room Entry - Jammu Links News
How does Citius Oncology Inc. compare to its industry peersBreakthrough stock performance - Jammu Links News
How does Citius Oncology Inc. generate profit in a changing economyPost Market Target Finder To Watch Now - Jammu Links News
What makes Citius Oncology Inc. stock attractive to long term investorsPortfolio Diversification Stock Ideas From Experts - metal.it
Published on: 2025-07-29 19:38:23 - metal.it
Citius Oncology Inc Stock (CTOR) Financials Data
There is no financial data for Citius Oncology Inc (CTOR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):